Purine inhibitors of human phosphatidylinositol 3-kinase delta

US9938281B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Abdelghani Achab · Melrose, US
• Michael D. Altman · Cambridge, US
• Yongqi Deng · Newton, US
• Solomon D. Kattar · Arlington, US
• Jason Katz · Leominster, US
• Joey L. Methot · Westwood, US
• Hua Zhou · Acton, US
• Meredeth A. McGowan · Boston, US
• Matthew Christopher · Brookline, US
• Yudith Garcia · Brookline, US
• Neville J. Anthony · Hatfield, US
• Francesc Xavier Fradera Llinas · Brookline, US
• Liping Yang · Arlington, US
• Changwei Mu · Beijing, CN
• Xiaona Wang · Beijing, CN
• Feng Shi · Beijing, CN
• Baijun Ye · Beijing, CN
• Sixing Zhang · Beijing, CN
• Xiaoli Zhao · Beijing, CN
• Rong Zhang · Zhejiang, CN
• Kin Chiu Fong · Shanghai, CN
• Xiansheng Leng · Beijing, CN

Key dates

• Filing date: Nov 15, 2013
• Grant date: Apr 10, 2018
• Expiry date: Nov 15, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.